<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3939">
  <stage>Registered</stage>
  <submitdate>5/06/2012</submitdate>
  <approvaldate>5/06/2012</approvaldate>
  <nctid>NCT01624142</nctid>
  <trial_identification>
    <studytitle>Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders</studytitle>
    <scientifictitle>A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia</scientifictitle>
    <utrn />
    <trialacronym>TAUSSIG</trialacronym>
    <secondaryid>20110271</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Severe Familial Hypercholesterolemia</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Evolocumab (AMG145)
Other interventions - Evolocumab (AMG145)

Experimental: Dose 1 of subcutaneous Evolocumab (AMG145) - Dose 1 of subcutaneous Evolocumab (AMG145)every month

Experimental: Dose 2 of subcutaneous Evolocumab (AMG145) - Dose 2 of subcutaneous Evolocumab (AMG145)every 2 weeks


Other interventions: Evolocumab (AMG145)
every month

Other interventions: Evolocumab (AMG145)
every 2 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subject incidence of treatment emergent adverse events - Subject incidence of treatment emergent adverse events</outcome>
      <timepoint>5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in low density lipoprotein-cholesterol - Percent change in low density lipoprotein-cholesterol from baseline open label at each scheduled visit</outcome>
      <timepoint>Every scheduled visit over 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in non-high density lipoprotein-cholesterol - Percent change in non-high density lipoprotein- cholesterol from baseline open label at each scheduled visit</outcome>
      <timepoint>Every scheduled visit over 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in apolipoprotein B - Percent change in apolipoprotein B from baseline open label at each scheduled visit</outcome>
      <timepoint>Every scheduled visit over 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in total cholesterol/high density lipoprotein-cholesterol ratio - Percent change in total cholesterol/high density lipoprotein-cholesterol ratio from baseline open label at each scheduled visit</outcome>
      <timepoint>Every scheduled visit over 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in apolipoprotein B/apolipoprotein A1 ratio - Percent change in apolipoprotein B/apolipoprotein A1 ratio from baseline open label at each scheduled visit</outcome>
      <timepoint>Every scheduled visit over 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in lipoprotein(a) - Percent change in lipoprotein(a) from baseline open label at each scheduled visit</outcome>
      <timepoint>Every scheduled visit over 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response rate of subjects with 15% or greater reduction in low density lipoprotein-cholesterol - Response rate of subjects with 15% or greater reduction in low density lipoprotein-cholesterol at each scheduled visit</outcome>
      <timepoint>Every scheduled visit over 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participated in a qualifying Evolocumab (AMG145) parent protocol OR

          -  Have a diagnosis of familial hypercholesterolemia AND

          -  Males and females = 12 to = 80 years of age

          -  Stable low-fat diet and lipid-lowering therapies for at least 4 weeks

          -  Low Density Lipoprotein - Cholesterol (LDL-C) &gt;=130 mg/dl (3.4 mmol/L) for subjects
             without diagnosed CHD/CHD risk equivalent OR LDL-C &gt;= 100 mg/dl (2.6 mmol/L) for
             subjects with diagnosed CHD or CHD risk equivalent OR apheresis patients have no LDL-C
             entry requirement

          -  Fasting triglycerides &lt; 400 mg/dL(4.5 mmol/L)

          -  Bodyweight of &gt; 40 kg or greater at screening for subjects less than 18 years of age</inclusivecriteria>
    <inclusiveminage>12</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  New York Heart Failure Association (NYHA) class III or IV or last known left
             ventricular ejection fraction &lt; 30%

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG) or stroke within 3 months of screening

          -  Planned cardiac surgery or revascularization

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>300</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>12/03/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>TAS,WA</recruitmentstate>
    <hospital>Research Site - Hobart</hospital>
    <hospital>Research Site - Perth</hospital>
    <postcode>7000 - Hobart</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>La Louvière</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>São Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Uherske Hradiste</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 13</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>New Territories</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Cinisello Balsamo (MI)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Napoli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ishikawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Beirut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucía</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Cataluña</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Galicia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study to assess the long term safety and efficacy of Evolocumab (AMG145)on Low Density
      Lipoprotein-Cholesterol (LDL-C) in subjects with severe familial hypercholesterolemia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01624142</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>